Purpose: To establish fair and non-discriminatory written selection criteria which will be used by the multidisciplinary transplant team when determining a patient's suitability for listing and/or transplantation.

Policy:

The following are the general indications for kidney transplantation:
- Creatinine clearance or calculated glomerular filtration rate (GFR) less than or equal to 20 mL/min (may preemptively list for GFR <30 to capture first measured value below 20)
- Chronic dialysis

The following are considered relative contraindications for kidney transplantation. Individually, these may not absolute contradictions, but are taken into consideration as total risk:
- Peripheral vascular disease
- History of CVA with residual deficits
- Diabetes with significant end organ damage
- Poor functional status as per Karnofsky Score
- Documented medical non-compliance
- Advanced cardiac disease which may include advanced cardiomyopathy or advanced coronary artery disease (CAD) not amenable to revascularization
- Severe Peripheral vascular disease (PVD) not amenable to revascularization
- Malignant arrhythmias refractory to treatment
- Severe malnutrition or cachexia
- Morbid obesity (BMI>40)
- Severe GI system disturbances which are not amenable to treatment
- Serious active infection not chronically suppressed with treatment
- Recent or active malignancy (safe timeframe determined by types, stage, treatments, and oncology recommendations)
- Severe, uncontrollable medical problems which impact non-renal organ function
- Severe, uncontrolled psychiatric disorders
- Inadequate psychosocial support
- Inadequate insurance/financial resources which would not allow for payment of procedure or follow up care
- Substance abuse which would, in the judgment of the transplant team, impair the patient's ability to comply with their medical regimen or otherwise endanger the kidney allograft, without an adequate period of abstinence or clearance from treatment program
- Pregnancy
- Any other condition which may be exacerbated by the transplantation process
### MGTI Policy Approvals:

<table>
<thead>
<tr>
<th>Signature</th>
<th>Name</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thomas Fishbein, MD</td>
<td>MGTI Physician Executive Director, Surgical Director Liver - Intestine</td>
<td>7/3/11</td>
</tr>
<tr>
<td></td>
<td>Matthew Cooper, MD</td>
<td>Surgical Director - Kidney Pancreas</td>
<td>7/3/17</td>
</tr>
<tr>
<td></td>
<td>Basit Javed, MD</td>
<td>Medical Director - Kidney-Pancreas</td>
<td>7/3/17</td>
</tr>
<tr>
<td></td>
<td>Toby Conlon, RN</td>
<td>MGTI Clinical Operations Director</td>
<td>7/3/17</td>
</tr>
<tr>
<td></td>
<td>Bridgette Diedrich, RN</td>
<td>MGTI Quality Director</td>
<td>7/3/2017</td>
</tr>
<tr>
<td></td>
<td>Jennifer Verbesey, MD</td>
<td>Transplant Fellowship Director</td>
<td>7/3/17</td>
</tr>
</tbody>
</table>